Annual Cash & Cash Equivalents
$71.64 M
-$15.25 M-17.55%
December 31, 2024
Summary
- As of March 10, 2025, JSPR annual cash & cash equivalents is $71.64 million, with the most recent change of -$15.25 million (-17.55%) on December 31, 2024.
- During the last 3 years, JSPR annual cash & cash equivalents has fallen by -$13.06 million (-15.42%).
- JSPR annual cash & cash equivalents is now -17.55% below its all-time high of $86.89 million, reached on December 31, 2023.
Performance
JSPR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$71.64 M
-$20.86 M-22.56%
December 31, 2024
Summary
- As of March 10, 2025, JSPR quarterly cash and cash equivalents is $71.64 million, with the most recent change of -$20.86 million (-22.56%) on December 31, 2024.
- Over the past year, JSPR quarterly cash and cash equivalents has stayed the same.
- JSPR quarterly cash and cash equivalents is now -44.64% below its all-time high of $129.40 million, reached on March 31, 2023.
Performance
JSPR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
JSPR Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -17.6% | 0.0% |
3 y3 years | -15.4% | -31.0% |
5 y5 years | +261.1% | -31.0% |
JSPR Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -17.6% | +87.3% | -44.6% | +87.3% |
5 y | 5-year | -17.6% | +261.1% | -44.6% | +261.1% |
alltime | all time | -17.6% | +261.1% | -44.6% | +261.1% |
Jasper Therapeutics Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $71.64 M(-17.6%) | $71.64 M(-22.6%) |
Sep 2024 | - | $92.50 M(-13.4%) |
Jun 2024 | - | $106.82 M(-9.8%) |
Mar 2024 | - | $118.47 M(+36.4%) |
Dec 2023 | $86.89 M | $86.89 M(-16.3%) |
Sep 2023 | - | $103.87 M(-10.3%) |
Jun 2023 | - | $115.81 M(-10.5%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2023 | - | $129.40 M(+238.3%) |
Dec 2022 | $38.25 M(-54.8%) | $38.25 M(-24.9%) |
Sep 2022 | - | $50.95 M(-16.2%) |
Jun 2022 | - | $60.81 M(-13.6%) |
Mar 2022 | - | $70.40 M(-16.9%) |
Dec 2021 | $84.70 M(+327.0%) | $84.70 M(-16.1%) |
Sep 2021 | - | $100.91 M(+408.6%) |
Dec 2020 | $19.84 M | $19.84 M |
FAQ
- What is Jasper Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Jasper Therapeutics?
- What is Jasper Therapeutics annual cash & cash equivalents year-on-year change?
- What is Jasper Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Jasper Therapeutics?
- What is Jasper Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Jasper Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of JSPR is $71.64 M
What is the all time high annual cash & cash equivalents for Jasper Therapeutics?
Jasper Therapeutics all-time high annual cash & cash equivalents is $86.89 M
What is Jasper Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, JSPR annual cash & cash equivalents has changed by -$15.25 M (-17.55%)
What is Jasper Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of JSPR is $71.64 M
What is the all time high quarterly cash and cash equivalents for Jasper Therapeutics?
Jasper Therapeutics all-time high quarterly cash and cash equivalents is $129.40 M
What is Jasper Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, JSPR quarterly cash and cash equivalents has changed by $0.00 (0.00%)